Trial Profile
Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Florquinitau F18 (Primary) ; Levetiracetam (Primary)
- Indications Mild cognitive impairment; Neurodegenerative disorders; Stroke; Traumatic brain injuries
- Focus Diagnostic use
- 07 May 2018 New trial record